Souhaitez-vous accéder aux communiqués récents ?

Agreement is the latest in a series of acquisitions and strategic collaborations that have bolstered Novartis' deep and diverse immuno-oncology pipeline Collaboration will co-develop Xencor's...

Findings are first to quantify magnitude of potential survival benefits if Entresto were prescribed to all eligible US HFrEF patients (as defined by authors) [1]   Cardiology experts highlight...

Novartis dirigera le développement de la molécule antipaludique KAF156 avec le soutien scientifique et financier de Medicines for Malaria Venture et en collaboration avec la Fondation Bill &...

Novartis wird die Entwicklung des Malariapräparats KAF156 mit wissenschaftlicher und finanzieller Unterstützung von Medicines for Malaria Venture in Zusammenarbeit mit der Bill & Melinda Gates...

Novartis will lead the development of antimalarial compound KAF156 with scientific and financial support from Medicines for Malaria Venture in collaboration with the Bill & Melinda Gates...

EXTEND study provides long-term safety data for Revolade that are consistent with the findings from the pivotal Phase III RAISE study[1,2] Immune thrombocytopenia (ITP) is a rare and potentially...

Three times as many patients with inadequately controlled PV without enlarged spleen had hematocrit control without phlebotomy on Jakavi® (ruxolitinib) vs BAT[1]  RESPONSE-2 complements data...

Sandoz' biosimilar etanercept candidate shows pharmacokinetic (PK) bioequivalence with no clinically meaningful differences in safety, tolerability and immunogenicity to the originator.[1]  ...

Phase II 20120295 study of AMG 334 met primary endpoint, confirming efficacy and safety in patients with chronic migraine over 12 weeks of treatment  Migraine is a leading cause of disability,...

Up to 80% of ankylosing spondylitis and 84% of psoriatic arthritis patients treated with Cosentyx® at two years had no radiographic progression in the spine or joints, respectively[1],[2]  ...